{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT04585477","nct_id":"NCT04585477","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04585477. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Subjects with detectable ctDNA (MRD+) will receive up to 12 cycles of durvalumab (1500mg dose by intravenous (by vein) injection every 28 days). ctDNA will be re checked following 2 cycles (8 weeks) of durvalumab and compared to baseline levels. In the absence of progression or toxicity after 2 cycles, subject will continue with durvalumab to complete 1 year of treatment about 10 additional cycles).\n\nSubjects will be monitored for secondary endpoints of progression free survival (PFS) and overall survival (OS).","label":"Cohort 1 minimal residue disease positive(MRD+)","type":"EXPERIMENTAL"},{"description":"Subjects with undetectable ctDNA (MRD) will receive Standard of care and no treatment","label":"Cohort 2 minimal residue disease negative (MRD-)","type":"ACTIVE_COMPARATOR"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2026-12-30","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer","Non-small Cell Lung Cancer Stage I","Non-small Cell Lung Cancer Stage II","Non-small Cell Lung Cancer Stage III"],"enrollment":{"count":80,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"AVENIO ctDNA Surveillance Kit","otherNames":["The AVENIO ctDNA Surveillance Kit"],"type":"DEVICE"},{"name":"Durvalumab","otherNames":["IMFINZI","MEDI4736"],"type":"DRUG"},{"name":"Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-07","lead_sponsor":"Stanford University","official_title":"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","overall_status":"SUSPENDED","phases":["PHASE2"],"primary_completion_date":{"date":"2026-12-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Decrease in ctDNA Level","timeFrame":"8 weeks"}],"references":[],"start_date":{"date":"2021-04-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","url":"https://clinicaltrials.gov/study/NCT04585477"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04585477"}